Precigen, Inc. - Common Stock (PGEN)

Precigen, Inc. (NASDAQ:PGEN) reported mixed Q4 results, with a loss of 1 cent per share beating estimates but sales of $4.565 million falling short.

Precigen (PGEN) Q4 2025 Earnings Call Transcript

This vacation ownership firm serves over 700,000 members and generates recurring revenue from real estate, financing, and resort operations.

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Precigen's Q3 2025 results show a huge revenue beat but a wider-than-expected loss. The key highlight is the full FDA approval and launch of its new therapy, PAPZIMEOS.

Precigen (PGEN) Q3 2025 Earnings Call Transcript

Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares

Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.

Discover the stocks with unexpected trading volume in today's session on the US markets.

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.